Compare FNLC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | ACRS |
|---|---|---|
| Founded | 1864 | 2012 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.9M | 314.2M |
| IPO Year | 1995 | 2015 |
| Metric | FNLC | ACRS |
|---|---|---|
| Price | $29.50 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 15.8K | ★ 1.4M |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.16 | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.11 | $1.05 |
| 52 Week High | $30.33 | $4.89 |
| Indicator | FNLC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 44.06 |
| Support Level | $28.88 | $3.33 |
| Resistance Level | $29.71 | $3.78 |
| Average True Range (ATR) | 0.72 | 0.25 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 64.29 | 6.54 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.